https://www.myeloma.org.uk/news/pharmaceutical-company-halts-access-to-car-t-cell-treatment-for-uk-myeloma-patients/ https://www.fiercepharma.com/pharma/johnson-johnson-bristol-myers-kite-pharma-car-t-cell-therapy-struggle-sloan-kettering https://www.fiercepharma.com/pharma/jj-partnered-car-t-...
德国埃尔朗根-纽伦堡大学(FAU)的 Georg Schett 教授团队在《新英格兰医学杂志》(NEJM)上发表了题为:CD19 CAR T-Cell Therapy in Autoimmune Disease — A Case Series with Follow-up 的研究论文。该论文报道了15名自身免疫病患者(8名系统性红斑狼疮患者、4名系统性硬化症患者和3名特发性炎性肌病患者)在接受CAR...
经CAR-T治愈的幸运小女孩Emily从12年接受治疗后,一直有安全性随访,她每年也会拍一张照片po到社交网站上。 相关链接及参考: Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL | Novartiswww.nova...
Mantle cell lymphoma (MCL) is a subtype of Non-Hodgkin lymphoma (NHL) of mature B-cells characterized by translocation, which is typically due to excess expression of Cyclin D1. Although with the progress in our knowledge of the causes for MCL and availa
新闻来源:CAR T-cell therapy effective for relapsed mantle cell lymphoma patients 由美国德克萨斯大学MD安德森癌症中心领导的一项为期一年的随访研究显示大多数对先前疗法有抵抗力的套细胞淋巴瘤(mantle cell lymphoma)患者可能会受益于靶向CD19的嵌合抗原受体 (CAR)T细胞(CAR-T)疗法。相关研究结果于2019年12月9日在...
The next-generation of immune cell therapies requires a new generation of cell analysis tools. Agilent is dedicated to supporting all phases of immune and CAR T cell therapy development with key technologies to enable high-efficiency gene editing and ass
CAR-T细胞技术是一种革命性的细胞疗法,2017年诺华公司推出第一代CAR-T疗法,这引领了其他形式的CAR-T药物的发展。 在23日的大会上,Dolcera中国区生物医药首席专家金实为大家带来“CAR-T Cell Therapy专利态势及研发趋势分析”相关观点分享。 知产前沿现将金老师的现场主题发言内容整理成文,供医药知识产权从业人员参考...
CAR T Cell Therapy Market Report published by value market research, it provides a comprehensive market analysis which includes market size, share, value, growth, trends during forecast period 2019-2025 along with strategic development of the key player with their market share. Further, the market...
近日,来自美国斯坦福大学医学院的Matthew J. Frank教授在Cancer Discovery杂志上发表文章Effects of an initial anti-CD19 CAR T-cell therapy on subsequent anti-CD22 CAR T-cell manufacturing and clinical outcomes in patients with r/r LBCL。本研究发现晚期白细胞分离术(CAR19治疗后6个月以上)导致残留的CAR...
外周T细胞淋巴瘤(Peripheral T Cell Lymphoma, PTCL)是一种罕见且高度侵袭性的血液恶性肿瘤,患者面临着极高的复发率和有限的治疗选择。复发/难治性PTCL患者的中位无进展生存期(Progression-Free Survival, PFS)和总体生存期(Overall Survival...